Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Cardiology, American University of Beirut Medical Center, Beirut, Lebanon.
Cardiol Young. 2024 Aug;34(8):1636-1644. doi: 10.1017/S1047951124025484. Epub 2024 Sep 13.
COVID-19, caused by the SARS-CoV-2 virus, has generated a global pandemic with a wide range of clinical manifestations. Cardiovascular complications are frequently observed in individuals with COVID-19, particularly those with preexisting cardiovascular risk factors or diseases. Cardiac biomarkers, including troponin, natriuretic peptides, and inflammatory markers, play a vital role in risk stratification, diagnosis, monitoring, and prognosis in COVID-19 patients. These biomarkers provide valuable insights into cardiac injury, myocardial stress, inflammation, and the prediction of adverse cardiovascular outcomes. This review aims to provide better understanding of how Cardiac biomarkers correlate to clinical manifestation of COVID-19.
We retrieved studies from PubMed, Medline, and Google Scholars that included results on cardiac biomarkers in COVID-19. Total of 14 studies were reviewed.
8 studies showed evidence of poor progression of the disease when there is increased troponin. 6 studies out of the 14 mentioned in this review showed positive correlation between mortality and elevation in cardiac biomarkers. This shows the significance of cardiac biomarkers in predicting the mortality in patients with COVID-19.
It was shown that elevated cardiac biomarkers were associated significantly to poor outcome of covid-19 infection. The outcomes that were linked to increased cardiac biomarkers included increased length of hospitalization, need of life sustaining treatment, myocarditis, invasive and non-invasive respiratory support, and even death were linked to elevated cardiac biomarkers levels.
由 SARS-CoV-2 病毒引起的 COVID-19 引发了广泛临床表现的全球大流行。心血管并发症在 COVID-19 患者中经常观察到，特别是那些存在心血管风险因素或疾病的患者。心脏生物标志物，包括肌钙蛋白、利钠肽和炎症标志物，在 COVID-19 患者的风险分层、诊断、监测和预后中起着至关重要的作用。这些生物标志物提供了有关心脏损伤、心肌应激、炎症和不良心血管结局预测的有价值的信息。本综述旨在更好地了解心脏生物标志物与 COVID-19 的临床表现之间的关系。
我们从 PubMed、Medline 和 Google Scholar 检索了包含 COVID-19 中心脏生物标志物结果的研究。共审查了 14 项研究。
8 项研究表明，当肌钙蛋白升高时，疾病的进展情况较差。在本综述中提到的 14 项研究中的 6 项表明，死亡率与心脏生物标志物升高之间存在正相关。这表明心脏生物标志物在预测 COVID-19 患者死亡率方面的重要性。
研究表明，升高的心脏生物标志物与 COVID-19 感染的不良结局显著相关。与升高的心脏生物标志物相关的结果包括住院时间延长、需要维持生命的治疗、心肌炎、侵入性和非侵入性呼吸支持，甚至死亡与升高的心脏生物标志物水平相关。
